|
News
- December 7, 2006 - PrimeNewswire
Samaritan
Pharmaceuticals Inc. (AMEX: LIV
- News),
a developer of innovative drugs, announced that the U.S. Food
and Drug Administration (FDA) has completed its regulatory
review of our IND (Investigational New Drug) application for
Caprospinol (SP-233), and has requested that additional information
be submitted in support of the safety Caprospinol, prior to
initiating Samaritan's proposed Phase I clinical study.
Samaritan filed an IND application for Caprospinol on October
30, 2006 and was subsequently granted an IND number by the
FDA. To understand the IND processes go to: http://www.samaritanpharma.com/html/ctind.html
Caprospinol
is a novel Alzheimer's drug candidate that Samaritan believes
has the potential to clear beta-amyloid plaques from the brain;
a problem that most researchers today believe, is the cause
of Alzheimer's. Since Caprospinol could be a significant breakthrough
in the treatment of Alzheimer's, Samaritan plans to provide
the information requested by the FDA as quickly as possible,
in order to continue moving our Caprospinol development program
forward.
http://www.samaritanpharma.com/html/videos.html
Dr.
Janet Greeson, CEO of Samaritan stated, ``The filing of this
IND speaks to the scientific merit of Caprospinol and the
research collaboration we have with Georgetown University.
This is the first IND as a result of our collaboration with
Georgetown University and we have high hopes Caprospinol will
make a significant contribution to the treatment of suffering
Alzheimer patients.''
Samaritan
Pharmaceuticals: ``We LIV . . . to Save Lives.''
Samaritan
is a small-cap Biotech, driven to discover, develop and commercialize
innovative therapeutics for AIDS, Alzheimer's, Cancer and
Heart disease patients. Look at http://www.samaritanpharma.com.
Please register on Website so we can notify you of upcoming
conference calls, news and events.
### |
